These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 19088802)
1. Beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia in apolipoprotein E-deficient mice. Xiao HB; Sun ZL; Lu XY; Li DZ; Xu JP; Hu YP Can J Physiol Pharmacol; 2008 Dec; 86(12):815-26. PubMed ID: 19088802 [TBL] [Abstract][Full Text] [Related]
2. Undaria pinnatifida soluble fiber regulates Angptl3-LPL pathway to lessen hyperlipidemia in mice. Xiao HB; Lu XY; Zhang HB; Sun ZL; Fang J J Physiol Biochem; 2013 Dec; 69(4):719-25. PubMed ID: 23595961 [TBL] [Abstract][Full Text] [Related]
3. 1,3,5,8-tetrahydroxyxanthone regulates ANGPTL3-LPL pathway to lessen the ketosis in mice. Xiao HB; Sun ZL; Zhou N Eur J Pharm Sci; 2012 May; 46(1-2):26-31. PubMed ID: 22342712 [TBL] [Abstract][Full Text] [Related]
4. Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice. Xiao HB; Liang L; Luo ZF; Sun ZL Eur J Pharmacol; 2018 Oct; 836():122-128. PubMed ID: 30096295 [TBL] [Abstract][Full Text] [Related]
5. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033 [TBL] [Abstract][Full Text] [Related]
6. The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models. Lin CY; Chen PY; Hsu HJ; Gao WY; Wu MJ; Yen JH Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293338 [TBL] [Abstract][Full Text] [Related]
7. ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice. Xiao HB; Wang JY; Sun ZL Exp Mol Pathol; 2017 Dec; 103(3):242-248. PubMed ID: 29104012 [TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. Inaba T; Matsuda M; Shimamura M; Takei N; Terasaka N; Ando Y; Yasumo H; Koishi R; Makishima M; Shimomura I J Biol Chem; 2003 Jun; 278(24):21344-51. PubMed ID: 12672813 [TBL] [Abstract][Full Text] [Related]
9. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. Chen YQ; Pottanat TG; Zhen EY; Siegel RW; Ehsani M; Qian YW; Konrad RJ J Lipid Res; 2021; 62():100068. PubMed ID: 33762177 [TBL] [Abstract][Full Text] [Related]
11. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). Lee EC; Desai U; Gololobov G; Hong S; Feng X; Yu XC; Gay J; Wilganowski N; Gao C; Du LL; Chen J; Hu Y; Zhao S; Kirkpatrick L; Schneider M; Zambrowicz BP; Landes G; Powell DR; Sonnenburg WK J Biol Chem; 2009 May; 284(20):13735-13745. PubMed ID: 19318355 [TBL] [Abstract][Full Text] [Related]
12. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998 [TBL] [Abstract][Full Text] [Related]
13. Physiological roles and regulation of hepatic angiopoietin-like protein 3 in Japanese Black cattle (Bos taurus) during the fattening period. Shikida R; Kim M; Futohashi M; Nishihara K; Lee H; Suzuki Y; Baek Y; Masaki T; Ikuta K; Iwamoto E; Uemoto Y; Haga S; Terada F; Roh S J Anim Sci; 2023 Jan; 101():. PubMed ID: 37317898 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111 [TBL] [Abstract][Full Text] [Related]
15. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice. Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299 [TBL] [Abstract][Full Text] [Related]
17. Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models. Gao WY; Chen PY; Hsu HJ; Liou JW; Wu CL; Wu MJ; Yen JH Biomed Pharmacother; 2024 May; 174():116598. PubMed ID: 38615609 [TBL] [Abstract][Full Text] [Related]
18. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice. Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096 [TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929 [TBL] [Abstract][Full Text] [Related]
20. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression. Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]